Prostaglandin F2a

Description

Prostaglandin F_2α (PGF_2α) is a widely distributed PG occurring in many species. It causes contraction of vascular, bronchial, intestinal, and myometrial smooth muscle, and also exhibits potent luteolytic activity. PGF_2α exerts its receptor mediated physiological activity at 50-100 nM. Maximal ovine myometrial contraction can be achieved at 125 nM PGF_2α in vitro.

History

Prostaglandins (PGs) are a class of important endogenous products with a wide range of physiological activities. PGs were first discovered and named by American scholar Von Eluer in 1930. In 1962, Bergstorm extracted two pure PGs (PGF1 and PGF2) and determined their chemical structures. In 1969, Willis first proposed that PGs are an inflammatory mediator in the body. Subsequently, various physiological and pharmacological activities of PGs have been intensively studied.

The Uses of Prostaglandin F2a

Prostaglandin F2α is one of the most biologically studied of the primary prostaglandins. Closely related to Prostaglandin E2 (PGE2) in that both prostaglandins are biosynthesized from the same precursors and that PGF2 is the synthetic reduction product of PGE2.

Background

Dinoprost has been investigated in Headache.

What are the applications of Application

Prostaglandin F2α is a potent smooth muscle contricting prostaglandin shown to inhibit adipocyte differentiation

Definition

ChEBI: Prostaglandin F2α is a prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.

Pharmacokinetics

Dinoprost is a natural prostaglandin F2α (PGF2α), which can directly act on the myometrium, stimulate the pregnant uterus to contract the uterine muscle, and can soften and dilate the cervix, so it can be used for induced abortion and late labor induction. However, due to the instability of dinoprost at room temperature, inconvenient storage and transportation, complex synthesis process and high cost, the application of dinoprost is difficult to popularize.

Safety Profile

Poison by subcutaneous, intravenous, and intramuscular routes. Moderately toxic by ingestion. Human and experimental teratogenic and experimental reproductive effects. Human reproductive effects by subcutaneous, intravenous, intramuscular, intraperitoneal, intravaginal, and intraplacental routes: postpartum depression and other maternal effects, abortion, and changes in measures of ferulity. Human teratogenic effects by intraplacental route: extra embryonic structures. Human systemic effects by intravenous route: hypermoulity, diarrhea, nausea or vomiting. Human mutation data reported. When heated to decomposition it emits acrid smoke and fumes

Metabolism

Not Available

Mode of action

Prostaglandin F2α (PGF2α) stimulates myometrial activity, relaxes the cervix, inhibits corpus luteal steroidogenesis, and induces luteolysis by direct action on the corpus luteum. In pregnancy, PGF2α is medically used to sustain contracture and provoke myometrial ischemia to accelerate labor and prevent significant blood loss in labor.